Superworth

Krystal Biotech price to sales ratio KRYS

Market value divided by revenue over the last twelve months, since 2024.

Today, Nov 2, 2026
19.9×
2-year median
19.5×
Against its 2-year history
53rd
percentile: 0 is its lowest day, 100 its highest
2-year range
10.8× to 34.8×
Peer median
7.0×

Krystal Biotech's price to sales ratio is 19.9× as of Nov 2, 2026.

That is above its 2-year median of 19.5×, close to the middle of its last 2 years.

Over that time it ranged from 10.8× in May 2025 to 34.8× in Aug 2024.

The median for 10 biotech stocks of a similar size is 7.0×.

Price to sales ratio over time

Open the interactive chart, with overlays and comparisons

Year by year

YearEnd of yearLowHigh
2026 so far19.9×18.4×26.5×
202519.6×10.8×19.6×
202419.0×19.0×34.8×

Against its peers

Companies in Biotechnology nearest Krystal Biotech's size, closest first, today.

CompanyPrice to sales ratio
KRYSKrystal Biotech19.9×
RGENRepligen12.4×
TECHBIO-TECHNE9.4×
HALOHalozyme Therapeutics8.8×
NBIXNeurocrine Biosciences4.4×
EXELExelixis7.1×
ALNYAlnylam Pharmaceuticals4.4×
INCYIncyte4.2×
UTHRUnited Therapeutics8.2×
ADMAAdma Biologics4.8×
VCELVericel6.8×
Peer median7.0×

Where Krystal Biotech ranks

What the price to sales ratio tells you

Market value divided by revenue over the last twelve months. Useful for companies with little or no profit yet, since sales are harder to make negative than earnings.

Ignores margins entirely. A software company at 10× sales with 30% margins can be cheaper than a grocer at 1× sales with 2% margins.

More on Krystal Biotech

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.